Gerald Crabtree, MD, a developmental biologist at Stanford, and a lead author of the study examined the potential rewiring of cancer cells to activate “cell death genes.”
The study focused on large B cell lymphoma. By linking together BRD4 and BCL6 proteins, researchers produced a molecule known as TCIP1 — capable of destroying diffuse large B cell lymphoma cell lines as well as those that are chemotherapy-resistant.
It could eventually be used on half of all cancers, Dr. Crabtree told The New York Times.
While the research didn’t lead to a drug development for cancer patients, the findings could be used as impetus for that in the future, according to the Times.
Leave a Reply